Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative chemoradiotherapy with capecitabine, oxaliplatin, and bevacizumab for locally advanced rectal cancer
ISRCTN50181543Phase 2Completed
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- May 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine, oxaliplatin and bevacizumab in rectal adenocarcinoma, sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoint: Histopathological complete remission rate. Started May 2008; status: completed.
02
Drugs
capecitabineoxaliplatinbevacizumab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ISRCTN50181543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN50181543.